Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02731638
Other study ID # 15-17989
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 2016
Est. completion date July 2018

Study information

Verified date September 2019
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Mycotic Antimicrobial Localized Injection (MALIN) is a randomized, masked, two-arm clinical trial investigating intrastromal voriconazole in the treatment of fungal corneal ulcers. There is currently little evidence to guide the treatment of fungal keratitis beyond topical anti-fungal drops, though intrastromal voriconazole and oral antifungal treatments are used as well. This study will provide evidence to guide the treatment of fungal keratitis in the future. The purpose of this study is to determine differences in microbiological cure for 3-day repeat cultures between different antifungal treatments. For this study, there will be 1:1 randomization to one of these two treatment groups: 1) topical natamycin plus intrastromal voriconazole injection or 2) topical natamycin alone.


Description:

The proposed study is a randomized controlled trial to determine whether intrastromal voriconazole improves outcomes in fungal keratitis. Patients presenting to the Aravind Eye Hospitals in Pondicherry, India for treatment of fungal keratitis will be recruited for the proposed study. Approximately 70 patients will be enrolled in the study. Subjects presenting with fungal keratitis will be randomized to receive topical natamycin plus intrastromal voriconazole or to receive topical natamycin alone. Subjects may also receive oral antifungals after day 3 at the discretion of the treating clinician. All study subjects will be followed for 3 months to evaluate response to treatment.

Investigators from the University of California, San Francisco (UCSF) will assist Aravind Eye Hospital with the study design, implementation, and analysis of the research, and will help fund the study. The investigators will visit Aravind to help with the study implementation. UCSF will play an important role in this study by assisting with the study design, implementation, analysis, and funding.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date July 2018
Est. primary completion date July 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Moderate to severe corneal ulcer that is smear positive for filamentous fungus

- Pinhole visual acuity worse than 20/70 in affected eye

- Basic understanding of the study as determined by the physician

- Commitment to return for follow up visits

Exclusion Criteria:

- Gram stain positive for bacteria or evidence of other concomitant infection (i.e. herpes, acanthamoeba)

- Impending or frank perforation at recruitment

- Involvement of sclera at presentation

- Non-infectious or autoimmune keratitis

- History of corneal transplantation or recent intraocular surgery

- No light perception in the affected eye

- Pinhole visual acuity worse than 20/200 in the unaffected eye

- Pregnant women

- Participants who are decisionally and/or cognitively impaired

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Intrastromal voriconazole
Subjects will receive three intrastromal voriconazole injections over 10 days. Intrastromal voriconazole injection is a routine procedure performed by Aravind Eye Hospital for fungal keratitis.
Natamycin
Subjects will receive topical 5% natamycin drops hourly for 3 days.

Locations

Country Name City State
India Aravind Eye Hospitals Pondicherry Tamil Nadu
United States Francis I. Proctor Foundation at UCSF San Francisco California

Sponsors (2)

Lead Sponsor Collaborator
University of California, San Francisco Aravind Eye Hospitals, India

Countries where clinical trial is conducted

United States,  India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Culture Positivity at Day 3 Using Potassium Hydroxide (KOH) Wet Mount to Test for Fungus Number of of participants with positive fungal cultures at 3 days 3 days
Secondary Best Spectacle-corrected Visual Acuity, as Measured by a Refractionist Best spectacle-corrected visual acuity using calibrated Original Series Early Treatment Diabetic Retinopathy Study eye charts and recorded as number of letter read. 3 weeks and 3 months
Secondary Scar Size Scar size, geometric mean 3 weeks and 3 months
Secondary Number of Participants With Scar Depth at the Anterior Third, Middle Third, and Posterior Third of the Cornea Number of participants with scar depth at the anterior third (0-33% depth), middle third (>33-67% depth), and posterior third (>67-100% depth) of the cornea, as measured on slit lamp exam. 3 weeks and 3 months
Secondary Corneal Thinning, as Measured by Pachymetry and OCT 6 months
Secondary Corneal Topography, as Measured by a Non-contact Imaging Topographer 6 months
Secondary Change in Quality of Life, Measured by the Indian Vision Function Questionnaire (IND-VFQ) 3 months
Secondary Corneal Neovascularization 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05705024 - Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells Phase 2
Completed NCT00324168 - Steroids for Corneal Ulcers Trial Phase 4
Completed NCT04484402 - Treatment of Patients With Inflammatory-dystrophic Diseases of the Cornea Using Autologous Stem Cells Phase 1/Phase 2
Completed NCT04820010 - Topical Insulin - Utility and Results in Neurotrophic Keratopathy in Stages 2 and 3
Recruiting NCT02570321 - Cross-linking for Corneal Ulcers Treatment Trial Phase 4
Completed NCT00386958 - A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers Phase 2
Completed NCT04054817 - ACRO Biocornea Clinical Trial in Taiwan N/A
Completed NCT00997035 - The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo Phase 3
Completed NCT02277054 - Safety and Effectiveness of Collagen-phosphorylcholine Bioengineered Cornea in Patients Requiring Lamellar Keratoplasty N/A
Recruiting NCT05313828 - Effect of Various Treatment Modalities on Dendritic Vial Ulcer
Recruiting NCT05255107 - Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers Phase 2/Phase 3
Recruiting NCT05255016 - Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers Phase 2/Phase 3
Completed NCT05891106 - AONDA Therapeutic Indication Study I
Terminated NCT00789646 - Painless Subconjunctival Antibiotic and Antifungal Injection in Corneal Ulcer Patients N/A
Not yet recruiting NCT05940376 - Topical Insulin in Neurotrophic Keratopathy After Diabetic Vitrectomy
Completed NCT05200000 - Wharton's Jelly Eye Drops in the Treatment of Chronic Keratitis Phase 1
Completed NCT01756456 - Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis. Phase 1/Phase 2
Active, not recruiting NCT01969786 - Village Integrated Eye Workers Trial N/A
Completed NCT01794312 - Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer Phase 3
Completed NCT04837534 - Improving the Follow up Rate for Pediatric Patients N/A